malaria vaccine

Sanaria’s PfSPZ-CVac Malaria Vaccine Achieves High Level Protection

In a report published in Nature, (Sterile protection against human malaria by chemoattenuated PfSPZ vaccine) investigators from University of Tübingen reported all nine subjects (100%) immunized with three doses of Sanaria® PfSPZ-CVac malaria vaccine were protected against Plasmodium falciparum malaria when exposed to the disease 10 weeks after last vaccine dose.

brain atrophy

Cladribine Tablets Significantly Reduced Brain Atrophy

  • Post hoc analysis of Phase III CLARITY study data recently published in Multiple Sclerosis Journal showed statistically significant reduction in brain atrophy in patients on a short course of investigational Cladribine Tablets over two years compared with patients receiving placebo
  • These findings correlated with effects on clinical progression as measured by the EDSS scale, a method of quantifying disability in multiple sclerosis

Merck KGaA, Darmstadt, Germany, a leading science and technology company, operating as EMD Serono in Canada, has announced the publication of the results of a post hoc analysis of the Phase III CLARITY study in Multiple Sclerosis Journal. The post hoc analysis showed that Cladribine Tablets reduced the annualised rate of brain volume loss – also known as brain atrophy – compared with placebo in patients with relapsing remitting multiple sclerosis (RRMS).

vBloc Therapy

vBloc Therapy Demonstrates Significant and Sustained Weight Loss and Glycemic Control

EnteroMedics Inc. (NASDAQ:ETRM), the developer of medical devices using neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders, has announced the publication of three-year data from the Company’s VBLOC DM2 Study of vBloc® Neurometabolic Therapy in obese patients with Type 2 diabetes. The publication, entitled “Vagal Nerve Block for Improvements in Glycemic Control in Obese Patients with Type 2 Diabetes Mellitus: Three-Year Results of the VBLOC DM2 Study,” was published in the Journal of Diabetes and Obesity and is available online here.


Rivaroxaban: The Only Non-Vitamin K Antagonist Oral Anticoagulant

Janssen Research & Development, LLC (Janssen) has announced that the Phase 3 COMPASS trial, evaluating the efficacy and safety of XARELTO® (rivaroxaban) for the prevention of major adverse cardiac events (MACE), including cardiovascular death, myocardial infarction and stroke in patients with coronary artery disease (CAD) or with peripheral artery disease (PAD), is stopping earlier than planned.